1
|
Mziray S, Maganda BA, Mwamwitwa K, Fimbo AM, Kisenge S, Sambu G, Mwalwisi YH, Bitegeko A, Alphonce E, Khea A, Shewiyo DH, Kaale E. Quality of selected anti-retroviral medicines: Tanzania Mainland market as a case study. BMC Pharmacol Toxicol 2021; 22:46. [PMID: 34446094 PMCID: PMC8390223 DOI: 10.1186/s40360-021-00514-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Accepted: 07/26/2021] [Indexed: 08/29/2023] Open
Abstract
Background Antiretroviral drugs (ARVs) have significantly reduced morbidity, mortality and improved the quality of life of people living with HIV infection. Poor quality ARVs may result in harmful consequences such as adverse drug reactions, treatment failure and development of drug resistant strains and sometimes death, which in turn may undermine the healthcare delivery system. To ensure optimal treatment outcomes, medicines quality control must be undertaken regularly. This study was aimed at evaluating the quality of ARVs circulating on the Tanzania Mainland market. Methods This was a survey study. ARVs samples were collected in 20 regions of Tanzania Mainland, between 2012 and 2018. All sampled ARVs were subjected to screening testing using the Global Pharma Health Fund® Mini-Lab kits. Sampled ARV’s that failed screening test or yielded doubtful results and 10 % (10 %) of all that complied with the screening test requirements were selected for full quality control testing. Quality control testing was conducted at the Tanzania Medicines and Medical Devices Authority (TMDA) laboratory a World Health Organisation prequalified. Samples collected from the medicine distribution outlets were also, subjected to product information review. Results A total of 2,630 samples were collected, of which 83.7 % (2200/2630) were from port of entry (POEs). All sampled ARVs were screened and conformed to the specifications, except of the fixed dose combination (FDC) lopinavir/ritonavir 0.27 % (7/2630) and lamivudine/zidovudine/nevirapine 0.27 % (7/2630) that failed the disintegration test. Out of the 100 samples selected for full quality control testing, 3 % of them failed to comply with the specifications, of which FDC stavudine/lamivudine/nevirapine failed disintegration and assay tests 2 % (2/100) and 1 % (1/100), respectively. Samples failing the assay test had low content of stavudine (86.6 %) versus specification limits (90 -110 %). Out of the 430 samples which were subjected to product information review, 25.6 % (110/430) failed to comply with the TMDA packaging and labelling requirements. Conclusions The quality of majority of ARVs circulating on the Tanzania Mainland market was good, even so, significant deficiencies on labelling and packaging were observed. These results call for continuous monitoring of quality of medicines circulating on the Tanzania Mainland market.
Collapse
Affiliation(s)
- Sophia Mziray
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Betty A Maganda
- Department of Pharmaceutics and Pharmacy Practice, Muhimbili University of Health and Allied Sciences, P.O BOX 65013, Dar es salaam, Tanzania.
| | - Kissa Mwamwitwa
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Adam M Fimbo
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Seth Kisenge
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Gerald Sambu
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Yonah H Mwalwisi
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Adonis Bitegeko
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Emmanuel Alphonce
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Akida Khea
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Danstan H Shewiyo
- Tanzania Medicines and Medical Devices Authority, P.O BOX 75150, Dar es salaam, Tanzania
| | - Eliangiringa Kaale
- Pharm R&D Lab, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P.O BOX 65013, Dar es salaam, Tanzania.,Department of Medicinal Chemistry, Muhimbili University of Health and Allied Sciences, P.O BOX 65013, Dar es salaam, Tanzania
| |
Collapse
|
2
|
Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc 2018; 21:e25201. [PMID: 30394678 PMCID: PMC6216177 DOI: 10.1002/jia2.25201] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Accepted: 10/08/2018] [Indexed: 12/14/2022] Open
Abstract
INTRODUCTION Non-alcoholic fatty liver disease is characterized by the presence of hepatic steatosis and can be associated with fibrosis progression, development of cirrhosis and liver-related complications. Data on the prevalence of liver fibrosis and steatosis in HIV patients remain contradictory in resource-limited settings. We aimed to describe the prevalence and factors associated with liver fibrosis and steatosis in patients with HIV mono-infection under long-term antiretroviral therapy (ART) in Rio de Janeiro, Brazil. METHODS Clinical assessment, fasting blood collection and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by transient elastography were performed on the same day for this cross-sectional study (PROSPEC-HIV study; NCT02542020). Patients with viral hepatitis co-infection, ART-naïve or missing data were excluded. Liver fibrosis and steatosis were defined by LSM ≥ 8.0 kPa and CAP ≥ 248 dB/m respectively. HIV history, cumulative and current ART regimens were evaluated. Multivariate logistic regression models adjusted for age and gender were performed. RESULTS In total, 395 patients (60% female; median age of 45 (IQR, 35 to 52) years, body mass index = 25.7 (23.2 to 29.4) kg/m2 , alanine aminotransferase = 30 (23 to 42) IU/L, duration of ART for 7 (4 to 14) years) were included. LSM and CAP were reliable in 93% (n = 367) and 87% (n = 344) respectively. The prevalence of fibrosis and steatosis were 9% (95% confidence interval (CI), 7 to 13) and 35% (95% CI, 30 to 40) respectively. The following factors were associated with fibrosis (odds ratio (OR) (95% CI)): older age (per 10 years; 1.80 (1.27 to 2.55); p = 0.001) and CD4+ count <200 cells/mm3 (7.80 (2.09 to 29.09), p = 0.002). Type 2 diabetes had a trend towards the presence of liver fibrosis (2.67 (0.96 to 7.46), p = 0.061). Central obesity (10.74 (4.40 to 26.20), p < 0.001), type 2 diabetes (9.74 (3.15 to 30.10), p < 0.001), dyslipidaemia (2.61 (1.35 to 5.05), p = 0.003) and metabolic syndrome (4.28 (2.45 to 7.46), p < 0.001) were associated with steatosis. A dominant backbone ART regimen of zidovudine (AZT), d4T, ddI or ddC was associated with steatosis (1.90 (1.07 to 3.38), p = 0.028) independently of metabolic features. CONCLUSION Integrated strategies for preventing non-communicable diseases in people with HIV mono-infection are necessary to decrease the burden of liver diseases. Clinical Trial Number: NCT02542020.
Collapse
Affiliation(s)
- Hugo Perazzo
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Sandra W Cardoso
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Carolyn Yanavich
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Estevão P Nunes
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Michelle Morata
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
- Plataform of Clinical ResearchNational Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Nathalia Gorni
- Department of NutritionNational Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Paula Simplicio da Silva
- Department of NutritionNational Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Claudia Cardoso
- Department of NutritionNational Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Cristiane Almeida
- Department of NutritionNational Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Paula Luz
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Valdilea G Veloso
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| | - Beatriz Grinsztejn
- Laboratory of Clinical Research in STI/AIDS (LAPCLIN‐AIDS)National Institute of Infectious Diseases Evandro Chagas‐Oswaldo Cruz Foundation (INI/FIOCRUZ)Rio de JaneiroBrazil
| |
Collapse
|
3
|
Ankrah DNA, Lartey M, Mantel-Teeuwisse AK, Leufkens HGM. Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study. BMC Infect Dis 2017; 17:664. [PMID: 28969591 PMCID: PMC5625598 DOI: 10.1186/s12879-017-2752-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 09/21/2017] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND There is limited information on patterns of treatment change among new initiators of highly active antiretroviral therapy (HAART) in the regions most affected by HIV/AIDS. This makes it difficult to identify the determinants of treatment change. In this retrospective cohort study, we examined treatment change patterns over a five-year period among initiators of HAART. METHODS De-identified data were obtained from the Fevers' Unit Database at the Korle-Bu Teaching Hospital. All adult treatment-naive patients who started treatment with first line HAART between 1st January, 2008 and 31st December, 2012 were followed over a minimum period of three months. The main outcome was the first treatment change, defined as the first substitution/switch in accordance with the standard treatment guidelines. Data were analyzed stratified by year of treatment initiation. Crude and adjusted hazard ratios were calculated. RESULTS A total of 3933 patients were followed with almost equal numbers of initiators per year. The mean age (standard deviation) at treatment initiation was 39 (10.3) years. The most prescribed HAART combination was AZT/3TC/EFV and overall for initiators zidovudine combination therapy was about 60%. Utilization of stavudine containing HAART increased gradually until 2010 and then dropped to zero. Over the study period, 44.9% of recorded deaths were from those initiated with a stavudine backbone, 41.1% from a zidovudine backbone, and 11.5% from a tenofovir backbone. Females had a significantly higher rate of treatment change compared to males (p-value = 0.0002), and d4T/3TC/EFV and d4T/3TC/NVP recorded independent treatment change hazard ratios of 12.05 (CI 9.58 to 15.16) and 12.03 (CI 9.27 to 15.61) respectively.. Kaplan-Meier curves showed that treatment change was higher among those who started treatment later in the study period compared with those who started earlier. CONCLUSION A major treatment change in the utilization of antiretroviral medicines in Ghana occurred during the study period which was associated with type of treatment, year of treatment, gender and disease stage. The influence of a policy change during the period may have made a significant impact.. For diseases involving life-long treatment in particular, it is important to monitor and periodically evaluation treatment utilization patterns.
Collapse
Affiliation(s)
- Daniel N. A. Ankrah
- Korle-Bu Teaching Hospital, P. O. Box 77, Korle-Bu, Accra, Ghana
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, the Netherlands
| | - Margaret Lartey
- Korle-Bu Teaching Hospital, P. O. Box 77, Korle-Bu, Accra, Ghana
- University of Ghana Medical School, P. O. Box GP, 4236 Accra, Ghana
| | - Aukje K. Mantel-Teeuwisse
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, the Netherlands
| | - Hubert G. M. Leufkens
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, the Netherlands
| |
Collapse
|
4
|
Vanobberghen F, Letang E, Gamell A, Mnzava DK, Faini D, Luwanda LB, Mapesi H, Mwamelo K, Sikalengo G, Tanner M, Hatz C, Furrer H, Battegay M, Glass TR. A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS One 2017; 12:e0180983. [PMID: 28719610 PMCID: PMC5515476 DOI: 10.1371/journal.pone.0180983] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Accepted: 06/24/2017] [Indexed: 01/18/2023] Open
Abstract
Objectives Our objectives were to describe trends in enrolment and clinical outcomes in the open, prospective Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) in the Morogoro region of southern Tanzania, and identify strengths and areas for improvement in the care of HIV-positive individuals in rural Tanzania. Methods We included adults (≥15 years) and children (<15 years) enrolled in the cohort in 2005–2014. The cohort underwent significant changes from autumn 2012 to optimise care. We evaluated mortality and loss to follow-up (LTFU) using competing risks methods, ART usage, opportunistic infections (OI), co-infections and laboratory abnormalities. Results Overall, 7010 adults and 680 children were enrolled; enrolment peaked in 2008 but has increased steadily since 2011. Among adults (65% female; median age 37 [interquartile range 31–45] years), the proportion referred from hospital wards quadrupled in 2013–14 versus earlier years. 653 (9%) adults died and 2648 (38%) were LTFU; the five-year cumulative probabilities of death and LTFU were 10.3% and 44.0%, respectively. Among children, 69 (10%) died and 225 (33%) were LTFU. The corresponding five-year probabilities were 12.1% and 39.6%. Adult ART use (regardless of eligibility) increased from 5% in 2005 to 89% in 2014 (similarly among children), with 9% on second-line therapy in 2014 (17% of children). OI diagnoses increased over time; tuberculosis prevalence at enrolment quadrupled from 6% in 2011 to 26% in 2014. The proportion of newly-enrolled participants assessed for laboratory abnormalities peaked at nearly 100% in 2014 (from a minimum of 24%), yet abnormality prevalences remained fairly constant. Conclusions In this cohort, ART usage improved dramatically and is approaching targets of 90%. Improved screening led to increases in detection of OIs and laboratory abnormalities, suggesting that a large number of these co-morbidities previously went undetected and untreated. Further work will address the high LTFU rates and implications for mortality estimates, and the management and outcomes of co-morbidities.
Collapse
Affiliation(s)
- Fiona Vanobberghen
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Emilio Letang
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
- Ifakara Health Institute, Ifakara, Tanzania
- ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clinic-Universitat de Barcelona, Barcelona, Spain
| | - Anna Gamell
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
- Ifakara Health Institute, Ifakara, Tanzania
| | | | | | | | | | | | | | - Marcel Tanner
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Christoph Hatz
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Hansjakob Furrer
- Bern University Hospital, Bern, Switzerland
- University of Bern, Bern, Switzerland
| | - Manuel Battegay
- University of Basel, Basel, Switzerland
- Department of Infectious Diseases and Hospital Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland
| | - Tracy R. Glass
- Department of Epidemiology & Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
- * E-mail:
| | | |
Collapse
|
5
|
Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft A, Kirk O. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. HIV Med 2015; 16:533-43. [PMID: 25988795 DOI: 10.1111/hiv.12254] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/03/2015] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The long-term side effects of stavudine (d4T) led to recommendations in 2009 to phase out use of this drug. We aimed to describe temporal patterns of d4T use across Europe. METHODS Patients taking combination antiretroviral therapy (cART) in EuroSIDA with follow-up after 1 January 2006 were included in the study. cART was defined as d4T-containing [d4T plus at least two other antiretrovirals (ARVs) from any class] or non-d4T-containing (at least three ARVs from any class, excluding d4T). Poisson regression was used to describe temporal changes in the prevalence of d4T use and factors associated with initiating d4T. RESULTS A total of 5850 patients receiving cART on 1 January 2006 were included in the current analysis, rising to 7768 patients on January 1 2013. During this time, the prevalence of d4T use fell from 11.2% to 0.7%, with an overall decline of 19% per 6 months [95% confidence interval (CI) 19-20%]. d4T use declined fastest in Northern Europe [26% (95% CI 23-29%) per 6 months], and slowest in Eastern Europe [17% (95% CI 16-19%) per 6 months]. In multivariable Poisson regression models, new d4T initiations decreased by 14% per 6 months [adjusted incidence rate ratio (aIRR) 0.86; 95% CI 0.80-0.91]. Factors associated with initiating d4T were residence in Eastern Europe (aIRR 4.31; 95% CI 2.17-9.98) versus other European regions and HIV RNA > 400 copies/mL (aIRR 3.11; 95% CI 1.60-6.02) versus HIV RNA < 400 copies/mL. CONCLUSIONS d4T use has declined sharply since 2006 to low levels in most regions; however, a low but persistent level of d4T use remains in Eastern Europe, where new d4T initiations post 2006 are also more common. The reasons for the regional differences may be multifactorial, but it is important to ensure that all clinicians treating HIV-positive patients are aware of the potential harmful effects associated with d4T.
Collapse
Affiliation(s)
- D Podlekareva
- CHIP, Department of Infectious Diseases Rigshospitalet, University of Copenhagen, Denmark
| | - D Grint
- UCL - Royal Free Campus, London, UK
| | - I Karpov
- Belarus State Medical University, Minsk, Belarus
| | - A Rakmanova
- Medical Academy Botkin Hospital, St Petersburg, Russia
| | - K Mansinho
- Hospital de Egas Moniz, Lisbon, Portugal
| | | | - I Zeltina
- Riga East University Hospital, Latvian Centre of Infectious Diseases, Riga, Latvia
| | - M Losso
- HIV Unit, Hospital JM Ramos Mejia, Buenos Aires, Argentina
| | | | - J D Lundgren
- CHIP, Department of Infectious Diseases Rigshospitalet, University of Copenhagen, Denmark
| | | | - O Kirk
- CHIP, Department of Infectious Diseases Rigshospitalet, University of Copenhagen, Denmark
| | | |
Collapse
|
6
|
Geubbels E, Amri S, Levira F, Schellenberg J, Masanja H, Nathan R. Health & Demographic Surveillance System Profile: The Ifakara Rural and Urban Health and Demographic Surveillance System (Ifakara HDSS). Int J Epidemiol 2015; 44:848-61. [PMID: 25979725 DOI: 10.1093/ije/dyv068] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2015] [Indexed: 11/13/2022] Open
Abstract
The Ifakara Rural HDSS (125,000 people) was set up in 1996 for a trial of the effectiveness of social marketing of bed nets on morbidity and mortality of children aged under 5 years, whereas the Ifakara Urban HDSS (45,000 people) since 2007 has provided demographic indicators for a typical small urban centre setting. Jointly they form the Ifakara HDSS (IHDSS), located in the Kilombero valley in south-east Tanzania. Socio-demographic data are collected twice a year. Current malaria work focuses on phase IV studies for antimalarials and on determinants of fine-scale variation of pathogen transmission risk, to inform malaria elimination strategies. The IHDSS is also used to describe the epidemiology and health system aspects of maternal, neonatal and child health and for intervention trials at individual and health systems levels. More recently, IHDSS researchers have studied epidemiology, health-seeking and national programme effectiveness for chronic health problems of adults and older people, including for HIV, tuberculosis and non-communicable diseases. A focus on understanding vulnerability and designing methods to enhance equity in access to services are cross-cutting themes in our work. Unrestricted access to core IHDSS data is in preparation, through INDEPTH iSHARE [www.indepth-ishare.org] and the IHI data portal [http://data.ihi.or.tz/index.php/catalog/central].
Collapse
Affiliation(s)
- Eveline Geubbels
- Ifakara Health Institute, Mikocheni, Dar es Salaam, Tanzania, INDEPTH Network, Kanda, Accra, Ghana, ALPHA Network, London School of Hygiene and Tropical Medicine, London, UK,
| | - Shamte Amri
- INDEPTH Network, Kanda, Accra, Ghana, Ifakara Health Institute, Ifakara Branch, Morogoro Region, Tanzania and
| | - Francis Levira
- Ifakara Health Institute, Mikocheni, Dar es Salaam, Tanzania, ALPHA Network, London School of Hygiene and Tropical Medicine, London, UK, Ifakara Health Institute, Ifakara Branch, Morogoro Region, Tanzania and
| | - Joanna Schellenberg
- Department of Disease Control and Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | - Honorati Masanja
- Ifakara Health Institute, Mikocheni, Dar es Salaam, Tanzania, INDEPTH Network, Kanda, Accra, Ghana
| | - Rose Nathan
- Ifakara Health Institute, Mikocheni, Dar es Salaam, Tanzania, INDEPTH Network, Kanda, Accra, Ghana
| |
Collapse
|